The record
- Vertical
- Vaccines
- Stage
- Series C
What they do
VitriVax is a vaccine company with a single-dose Lyme disease vaccine candidate and an ALTA vaccine platform. On November 18, 2026, it announced an oversubscribed $87 million Series C co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures, with Eli Lilly and other existing investors participating. The financing will support taking the Lyme vaccine candidate into first-in-human trials and expanding the pipeline.
Investors
- F-Prime
- NEA
- RA Capital Management
- Sanofi Ventures
- Eli Lilly
History and progression
How VitriVax got here, step by step.
18 November 2026
$87 million Series C
VitriVax announced an oversubscribed $87 million Series C co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures, with Eli Lilly and other existing investors participating, to advance its single-dose Lyme vaccine candidate into first-in-human trials and expand its pipeline.
Key products
- Single-dose Lyme disease vaccine candidate
- Candidate intended to advance into first-in-human trials with the November 2026 financing.
- ALTA
- VitriVax vaccine platform.
Recent news
18 November 2026
VitriVax announces $87 million Series C financing
Related companies
Your daily HealthTech Signal
No hype. Just signal.
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: